Julius Clinical invites you to their event

Clinical Consequences of the New MASLD Nomenclature

About this event

On June 27th, we will organise the webinar:

Clinical Consequences of the New MASLD Nomenclature

During this webinar, our speaker and hosts will dive into the following topics:

  • Is the MASLD nomeclature of prognostic relevance?
  • Do we need to re-validate all NILTs after the new nomenclature?
  • Considerations for "the new kid in town": MetALD

Speaker: Prof. Maja Thiele

Hosts: Prof. Manuel Castro Cabezas & Prof. Christophe Moreno

Audience: Clinicians, researchers, pharmaceutical industry workers, public health workers

Hosted by

  • Team member
    Julius Clinical

Julius Clinical

The Academic CRO

Julius Clinical is the Academic Contract Research Organisation (CRO) that manages global clinical drug trials that will have a major impact on medicine and make a real difference to people’s lives around the world.